X

Clinical Trials

Contact Us

Rare Tumor

NCI 10231 (MBMC only)

NCORP Tissue Procurement Protocol: An NCI Cancer Moonshot Study


A031702 (Miscellaneous GU Tract Histologic Variants cohort temporarily suspended 9/23/19)

Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors


S1609 (NCT02834013)

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors


MATCH: EAY131 (NCT02465050)

MATCH: Molecular analysis for therapy choice. Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors or lymphoma.